Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.

A method for screening host cells expressing a target protein is provided. The method includes the following steps: providing an expression vector, the expression vector including a promoter, a gene encoding a target protein and an FTH1 gene; transfecting the host cells with the expression vector; culturing the host cells in a medium; and adding iron ions to the medium, and screening the surviving host cells to obtain the host cells expressing the target protein. An expression vector and a method for establishing a cell line stably expressing an exogenous recombinant gene are also provided.

Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.

Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.

The invention provides methods for diagnosing prostate cancer. The invention also provides methods for determining the prognosis and efficacy of STEAP1-ADC therapy in patients with prostate cancer, specifically metastatic castration resistant prostate cancer (mCRPC).

Provided herein are antibodies which bind to ceruloplasmin and are useful for various applications, including detecting ceruloplasmin and immunocapturing ceruloplasmin in biological samples. The antibodies are useful in methods of measuring non-ceruloplasmin-bound copper concentrations and labile-bound copper concentrations in biological samples.

Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia.

The invention provides methods for diagnosing prostate cancer. The invention also provides methods for determining the prognosis and efficacy of STEAP1-ADC therapy in patients with prostate cancer, specifically metastatic castration resistant prostate cancer (mCRPC).

Disclosed are methods of treating a copper metabolism-associated disease or disorder, such as Wilson disease (WD) in a subject, particularly in a subject who is from about 3 years old to less than about 18 years old. Also disclosed are compositions comprising bis-choline tetrathiomolybdate for use in the treatment of a copper metabolism-associated disease or disorder, such as Wilson disease (WD) in a subject, particularly in a subject who is from about 3 years old to less than about 18 years old. Also disclosed are uses of a composition comprising bis-choline tetrathiomolybdate for the manufacture of a medicament for treating a copper metabolism-associated disease or disorder, such as Wilson disease (WD) in a subject, particularly in a subject who is from about 3 years old to less than about 18 years old.

Provided herein are 3D bioassays to measure antibody-dependent cell-mediated cytotoxicity (ADCC). In particular, provided is a method for assessing ADCC comprising contacting an antibody or a functional antibody fragment thereof with a target cell and an effector cell expressing FcR, in a 3D cell culture under a condition allowing the interactions between those substances; and detecting the changes in the expression levels of biomarkers CXCL9, CXCL10 and CXCL11 and 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 of the biomarkers selected from UBD, IDOL, STEAP4, JAG1, APOL4, GBP4, CD274, GBP5, CCL3 and CCL4; and assessing ADCC of the antibody based on the expression results. Also provided are the use and product relate to the method.